Bleeding study for multiple myeloma patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at bleeding risks in people newly diagnosed with multiple myeloma who are taking blood thinners (aspirin or a low-molecular-weight heparin). You'll fill out a few questionnaires to help doctors learn how to better prevent bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with multiple myeloma.
- You are taking a blood thinner like aspirin or low-molecular-weight heparin (LMWH) to prevent clots.
- You are willing and able to fill out questionnaires.
- You do not object to your data being used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how blood thinners are used in people with newly diagnosed multiple myeloma. The goal is to find better ways to prevent blood clots during treatment.
This trial is testing whether aspirin or a blood thinner called rivaroxaban can best prevent harmful blood clots in people newly diagnosed with multiple myeloma who have a high risk of developing clots. It aims to find a safer and more effective way to protect you during treatment.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
This trial studies myeloma (and closely related blood disorders) by using extra blood or bone marrow samples for lab research. It aims to help discover new ways to understand or treat myeloma.
This study is testing whether a blood test that measures a protein called BCMA can help doctors know if your multiple myeloma is getting worse. You may be able to join if your myeloma has come back or not responded to at least two prior treatments, and you have not taken the drug Ruxolitinib before.
This trial screens first-degree relatives of people with multiple myeloma to check for early signs of the disease before symptoms. It may help doctors understand risk in families and find problems sooner if they occur.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.